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Myelodysplastic syndromes (MDSs) are a heteroge-
neous group of myeloid neoplasms with defects in
hematopoietic stem and progenitor cells (HSPCs)
and possibly the HSPC niche. Here, we show that
patient-derived mesenchymal stromal cells (MDS
MSCs) display a disturbed differentiation program
and are essential for the propagation of MDS-initi-
ating LinCD34+CD38 stem cells in orthotopic
xenografts. Overproduction of niche factors such
as CDH2 (N-Cadherin), IGFBP2, VEGFA, and LIF is
associated with the ability of MDS MSCs to enhance
MDS expansion. These factors represent putative
therapeutic targets in order to disrupt critical he-
matopoietic-stromal interactions in MDS. Finally,
healthy MSCs adopt MDS MSC-like molecular fea-
tures when exposed to hematopoietic MDS cells,
indicative of an instructive remodeling of the micro-
environment. Therefore, this patient-derived xeno-
graft model provides functional and molecular
evidence that MDS is a complex disease that in-
volves both the hematopoietic and stromal com-
partments. The resulting deregulated expression of
niche factors may well also be a feature of other
hematopoietic malignancies.824 Cell Stem Cell 14, 824–837, June 5, 2014 ª2014 Elsevier Inc.INTRODUCTIONMyelodysplastic syndromes (MDSs) are a heterogeneous
group of malignant clonal diseases that affect older individuals
(median age 68–75 years) with an incidence in the range of 3–
10/100,000. MDSs are characterized by ineffective hematopoi-
esis and the presence of dysplastic cells in the bone marrow
as well as peripheral cytopenias. Clinically, patients present
with symptoms such as anemia, bleeding, or infection. Classi-
fication of MDS is carried out according to risk-score systems
such as the World Health Organization (WHO) classification or
the international prognostic scoring systems (IPSS and IPSS-
R). These scoring systems allow the accurate segregation of
patients according to prognosis and are used to adapt thera-
peutic options to individual patients (Garcia-Manero, 2012).
Treatment options for MDS range from best supportive care,
hematopoietic growth factors, or immunomodulatory drugs
such as lenalidomide in lower-risk patients to treatment with
DNA demethylating agents, cytotoxic chemotherapy, or he-
matopoietic stem cell (HSC) transplantation with curative intent
for patients in higher-risk subgroups (Garcia-Manero, 2012).
Genome-wide discovery approaches recently revealed a num-
ber of genetic lesions in patients with MDS that provide valu-
able insights into the underlying biology of MDS (Haferlach
et al., 2014; Bejar et al., 2011, 2012; Papaemmanuil et al.,
2013; Walter et al., 2012). This knowledge has been success-
fully used to generate genetic mouse models of MDS (Abdel-
Wahab et al., 2013; Muto et al., 2013). However, it is expected
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ity and complexity seen in patients.
Several attempts to generate a robust xenograft model in
immunodeficient mice have been undertaken, but these have
demonstrated inconsistent, transient, and low levels of engraft-
ment, particularly with regard to samples taken from lower-risk
MDS patients (Martin et al., 2010; Muguruma et al., 2011; Tha-
nopoulou et al., 2004). In addition, distinguishing normal HSC
from MDS stem cell (MDS HSC) engraftment was difficult, given
that large cytogenetic lesions that allow easy tracking of the
malignant clone are only present in about half of the MDS
patients and that no distinguishing cell-surface markers have
been identified to date (Martin et al., 2010; Muguruma et al.,
2011; Thanopoulou et al., 2004). Most importantly, patient sam-
ples that did engraft in these studies represented higher-risk
MDS, which are closer to acute myeloid leukemia (AML) (Pang
et al., 2013). Recently, several studies suggested that alterations
in the bone marrow niche influence the development of myeloid
neoplasms (reviewed by Raaijmakers, 2012). Mice deficient for
retinoic acid receptor g (RARg) develop myeloproliferative syn-
dromes induced solely by the RARg-deficient microenvironment
(Walkley et al., 2007). More recently, MDS could efficiently be
induced in mice in which DICER, a gene encoding a microRNA
processing enzyme, was deleted in osteoprogenitor cells (Raaij-
makers et al., 2010), whereas expression of an activated form of
b-catenin in osteoblasts alters the differentiation of hematopoi-
etic progenitors, leading to the development of AML (Kode
et al., 2014). Finally, in chronic myeloid leukemia (CML), niche
cells have been shown to exert a protective role in the response
to Imatinib in vitro (Zhang et al., 2013). Altogether, these reports
strongly support the hypothesis that abnormal niche environ-
ment provides ‘‘fertile soil’’ for the expansion of the neoplastic
cells in vivo.
RESULTS
Cotransplantation of CD34+ Cells with Patient-Derived
MSCs Allows Efficient and Long-Term MDS
Reinstallment in NSG Mice
Our study is based on the analysis of 31 MDS patients who were
classified as follows: IPSS low risk (n = 7), intermediate-1 risk
(n = 24), and WHO 2008 classifications MDS 5q (n = 7), MDS
RCMD (n = 14), MDS RAEB I (n = 6), MDS-U (n = 2), and MDS
RARS (n = 2; Table S1). Among these, 24 were tested for their
ability to propagateMDS in a xenograft setting (low risk, n = 5; in-
termediate-1 risk, n = 19). Based on the hypothesis that disease-
propagating cells (DPCs) in lower-riskMDS form a functional unit
with their stromal niche cells, we decided to compare the
engraftment of MDS-derived CD34+ cells injected either alone
or in combination with their corresponding in vitro expanded
mesenchymal stromal cells into the bone marrow cavity of sub-
lethally irradiated NOD/LtSz-scid IL2Rgc/ (NSG) mice (Fig-
ure 1A). We opted for the intrabone injection because of the hy-
pothesis that hematopoietic and stromal cells may require
physical interaction. Then,micewere analyzed for human chime-
rism (human CD45 [hCD45] expression) at 16–28 weeks post-
transplantation. Of the cases transplanted with CD34+ cells
alone, only one of seven samples (MDS14) showed engraftment
above the 1% threshold we set for this study (one of three miceengrafted; Figure 1B, left). In contrast, coinjection of CD34+ cells
with MDS MSCs resulted in a significantly higher engraftment in
70% of the patient samples analyzed (14 of 20 patients; range =
1%–22%; p = 0.026; Figure 1B). A direct comparison with the
identical CD34+ MDS samples was possible for four patients:
MDS14, MDS17, MDS18, and MDS19 (Figure 1B). MDS17 did
not engraft in either condition. Importantly, the remaining three
samples showed an enhanced engraftment with MDS MSCs,
further validating our finding.
Abnormal Lineage Distribution and Clonal Tracking of
MDS Cells in the Xenograft
Bone marrow cells from engrafted mice were further analyzed
with lineage-specific antibodies (CD19 for B cells and CD33 for
myeloid cells). When compared to mice repopulated with age-
matched healthy old CD34+ cells, most recipients of MDS cells
had a significant disproportionate output of myeloid cells
(MDS, 70.3% ± 5.3%; healthy, 10.7% ± 1.4%; p < 0.0001; Fig-
ure 1C). Four patients (MDS12, MDS24, MDS38, and MDS52)
showed an increased B lymphoid output, which may indicate
the engraftment of healthy stem cells as opposed to an MDS-
derived clone (Figure 1C). To ascertain the origin of the xeno-
grafted cells (MDS or healthy), we used several methods to
molecularly track the lesions that were initially identified in the
patients. Primary hematopoietic cells from each patient were
analyzed with chromosomal banding and SNP array (SNP-A)
as well as targeted next-generation sequencing (NGS), interro-
gating acquired mutations in 17 frequently mutated genes
described in MDS (Table S2). This strategy allowed us to identify
at least one traceable lesion for all patients included in this study
with the exception ofMDS19 (Table S1). Therefore, bonemarrow
from patient 19 was subjected to whole-exome sequencing,
which revealed the presence of a BCORL1 mutation in 58% of
the bone marrow cells (corresponding to a mutational allele fre-
quency of 29%). Importantly this mutation was not detected in
MSCs isolated from the same patient, thereby excluding a
germline origin (data not shown). For each engrafted mouse,
hCD45+ cells were purified by fluorescence-activated cell sort-
ing (FACS) and analyzed with SNP-A or interphase fluorescence
in situ hybridization (FISH) analysis for the detection and quanti-
fication of del(5q) or del(21q) (Figures 1D–1F and Table S3) as
well as by employing specific pyrosequencing assays in order
to track and quantify the mutated alleles (Figure 1G). Table S3
provides a comprehensive summary of the mutational allele fre-
quencies detected in human cells isolated from all xenografted
mice displayed in Figure 1B. In the case of cytogenetic aberra-
tions, the numbers refer to the percentage of analyzed cells
that scored positive for the lesion, whereas, for heterozygous
point mutations, these numbers refer to the allele frequency of
the mutated variant. These data confirm that these cells carried
the same lesion(s) as the one(s) identified in the original patient
samples. Furthermore, we could even observe a significant
expansion of an MDS clone carrying both an SF3B1 mutation
and a del(5q) in the mouse engrafted with patient MDS11 cells
(Figures 1D and 1E). Even though human cells isolated from
MDS16 did not carry any lesion, they exhibited the typical
marked myeloid bias observed in most other MDS samples
that were validated by molecular analysis (Figure 1C). The pre-
dominant B cell population isolated from xenografts of patientsCell Stem Cell 14, 824–837, June 5, 2014 ª2014 Elsevier Inc. 825
Figure 1. Enhanced Engraftment of Lower-Risk MDS by Cotransplantation of Patient-Derived MSCs
(A) Schematic experimental setup. MDSCD34+ were injected in the bonemarrow cavity of sublethally irradiated NSGmice either alone (CD34+) or in combination
with MDS-derived MSCs (CD34+ + MSC).
(B) Percentage of hCD45+ cells in the bone marrow of xenografted mice (%hCD45+) analyzed 16–28 weeks posttransplantation. The red dotted line indicates the
1% threshold used in this study to define positive engraftment. Numbers on the x axis are patient IDs. Each dot represents one mouse. Mean engraftment values
were compared in the two cohorts with a Mann-Whitney test (p = 0.026). Asterisks indicate paired patient samples analyzed side by side.
(legend continued on next page)
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however, the CD33+ fraction did (Table S3), indicating the coen-
graftment of a healthy and an MDS stem cell. Patient 38 en-
grafted three mice, one of which showed a significant MDS
engraftment, whereas the two others mostly gave rise to a B
lymphoid-biased graft with cells that did not carry the lesion
seen in the original patient.
Human MDS-Initiating Cells display Long-Term Self-
Renewal Activity in Serial Transplantation Assays
As expected, human cells with stem cell (CD34+CD38) and
progenitor (CD34+CD38+) phenotypes were detectable in all
xenografts with MDS MSCs, albeit at varying frequencies (Fig-
ure 2A and data not shown). In addition, analysis of myeloid,
and in some cases B lymphoid, cells isolated from NSG xeno-
grafts showed that they carried the molecular lesion found in
the primary patient (Figures 2B and 2C and data not shown).
Because cells with a hematopoietic stem and progenitor cell
(HSPC) phenotype were readily detectable in primary xeno-
grafts, we addressed whether they could be serially transplanted
into secondary recipients. Cells with an hCD45+CD34+ pheno-
type were isolated with FACS from amouse previously engrafted
with CD34+ cells of patient MDS14 (Figure 2D). The presence of
the chromosome 5q deletion was quantified by FISH analysis of
FACS-purified human cells (Figure 2E). Then, 10 weeks post-
transplantation, two of three recipients engrafted with as little
as 6,500 transplanted CD45+CD34+ cells along with MDS
MSCs (Figure 2F). Even though the contribution was below
1%, these cells were positive for del(5q), demonstrating their
origin from MDS14 (Figure 2E). Similar results were obtained
with serial transplantation of CD45+ or CD45+CD34+ cells from
patients 10 and 23, respectively (Figure S1A). These data
demonstrate that lower-risk MDS stem cells can harbor long-
term self-renewal activity.
Higher MDS Engraftment and Typical Signs of Dysplasia
in NSGS Recipients
In vitro studies suggest that MSCs and growth factors have
synergistic effects on the expansion of HSPCs (Walenda
et al., 2011). However, it is well known that a subset of murine
growth factors exhibit limited cross-reactivity with the human
orthologs of their receptors, which could limit the growth of
human stem cells in a murine host (Wunderlich et al., 2010).
Therefore, we attempted to further improve human MDS
engraftment by using the recently described NSGS mouse
strain that constitutively expresses the human cytokines IL3,
GM-CSF, and stem cell factor (SCF). These mice have been(C) Immunophenotyping of hCD45+ cells isolated from the bone marrow of mice e
total of 33 mice) or healthy age-matched CD34+ cells (n = 2 healthy donors eac
showed a significant skewing toward myeloid output (unpaired Student’s t test,
(D) High-density SNP array analysis. The shown profile depicts a heterozygou
corresponding xenograft (bottom).
(E) Molecular analysis of MDS11 primary patient sample (Pry BM) and its correspo
mutation (allelic frequency = 22%) and a deletion of chromosome 5q (35% of ce
primary patient sample. In the xenograft, MDS cells carrying these lesions expan
(F) Interphase FISH for tracking the chromosome 5q deletion on FACS-sorted hu
(G) Example of a quantitative pyrosequencing assay designed to track and quanti
the mutated allele is indicated with a red arrow. Bone marrow from healthy old d
See also Tables S1, S2, and S3.shown to improve the engraftment of primary human AML
(Wunderlich et al., 2010). More recently, investigators demon-
strated enhanced normal human myelopoiesis after injection
of CD34+ human cord blood cells in this strain (Miller et al.,
2013). We compared the engraftment of four patient samples
side by side in age-matched NSG and NSGS mice also coin-
jected with MDS MSCs. This analysis revealed an augmented
human chimerism in NSGS in comparison to NSG mice (Fig-
ure 3A), which increases over time in the NSGS mice, as indi-
cated by an illustrative example (Figure S1B). Similar to the
NSG model, characteristic molecular lesions present in the
samples from the patients were also found in the xenografted
cells (Figures S1C–S1G). These data are summarized in Fig-
ure 3A, in which the mean frequency of MDS cells (hCD45+ cells
carrying an MDS lesion) in the bone marrow of NSG or NSGS
mice are displayed. These results show a consistently
enhanced MDS disease burden in the NSGS strain.
Given that the presence of dysplastic cells is one of the main
clinical features of MDS, we performed Pappenheim staining of
bone marrow smears in order to analyze the morphology of
engrafted cells. This analysis revealed readily detectable
dysplastic cells exclusively in mice engrafted with MDS-derived
cells (Figure 3B). As shown in Figure 3B, typical signs of
dysplastic erythropoiesis with megaloblastic and vacuolized
proerythroblasts in both the primary patient bone marrow
sample (top right) and the corresponding xenograft (Figure 3B,
bottom right) is apparent. Importantly, these dysplastic signs
were absent in unmanipulated NSGS mice (Figure 3B, top left)
as well as mice engrafted with healthy age-matched CD34+ cells
(Figure 3B, bottom left). Altogether, these data indicate that
expression of human cytokines further improves the engraftment
and growth of human MDS cells in mice.
MDS Initiating and Propagating Cells Have a
Lin–CD34+CD38– Phenotype, Retain Multipotency, and
Display Variegated Clonality
The identification of the DPC in human MDS has so far been
hampered by the lack of a transplantation assay for this dis-
ease. Molecular alterations described in MDS are rarely found
in lymphoid compartments, raising the possibility that the
MDS-DPC might be a myeloid restricted progenitor rather
than an early stem cell harboring both myeloid and lymphoid
potential. Alternatively, genetic and/or epigenetic changes in
MDS stem cells might prevent their ability to commit to the
lymphoid lineage. To address this issue, erythroid (CD235a+
CD71+), myeloid (CD33+), and lymphoid (CD3+CD19+) cells
from five primary samples from MDS patients were isolatedngrafted with either MDS (n = 12 patients displayed in B and transplanted in a
h transplanted in three mice) both injected with MDS MSCs. MDS xenografts
p < 0.0001).
s deletion of chromosome 5q in patient MDS11 bone marrow (top) and its
nding xenograft in an NSG mouse (NSG). Data show the presence of a SF3B1
lls positive; i.e., 17.5% relative allelic frequency displayed in the graph) in the
d to allelic frequencies of >40% for SF3B1 and >35% for del(5q).
man CD34+ cells from a mouse engrafted with patient sample MDS14 cells.
fy mutations in primary samples as well as xenografted fractions. The burden of
onors (>60 years) was used as a control.
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Figure 2. MDS Cells Sustain Long-Term Multilineage Hematopoiesis in NSG Mice
(A) Representative FACS plots showing that human cells with progenitor (CD34+CD38+) and stem cell (CD34+CD38) phenotypes are readily detectable in the
xenografts with MDS MSCs 16–28 weeks posttransplantation.
(B) The indicated fractions were purified by FACS and subjected to mutational allele frequency quantification by pyrosequencing.
(B and C) Gating scheme used to sort B lymphoid (CD19+) andmyeloid cells (CD33+) form the bonemarrow of mice engrafted with cells from patients MDS18 and
MDS52.
(D) Workflow of serially transplanting a primary xenografted sample from MDS14 into three secondary recipients 16 weeks after the initial transplant.
(E and F) Secondary xenografts, which were generated by transplanting as little as 6,500 CD34+ cells from the primary mouse retain the primary del(5q) molecular
lesion as detected by FISH analysis of FACS-sorted fractions depicted in (F). In all FACS experiments, dead cells were excluded with 7AAD.
See also Figure S1.
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Figure 3. NSGS Mice Further Enhance the Engraftment of Dysplastic MDS Cells
(A) Side by side comparison of engraftment levels in NSG andNSGSmice injectedwith CD34+ +MDSMSCs derived from four patients (MDS16, MDS18,MDS23,
and MDS28). Data show the mean frequency of MDS cells as determined by multiplication of the fraction of hCD45+ cells carrying the MDS-specific molecular
lesion by the percentage of hCD45+ cells in the bone marrow of engrafted mice.
(B) Representative example of a Pappenheim staining of bonemarrow smears of an untreated native NSGSmouse (upper left), primaryMDS patient bonemarrow
(upper right), NSGS mouse xenotransplanted with CD34+ cells from a healthy donor (lower left), and NSGS mouse xenotransplanted with CD34+ cells from the
corresponding MDS patient (lower right). The primary patient bone marrow showed pronounced signs of dysplasia most predominant in the erythropoietic
compartment with megaloblastic and vacuolized proerythroblasts (red arrows with ‘‘E’’). These can also be readily detected in the xenografted NSGS mice from
this patient (lower right, red arrow with ‘‘E’’).
See also Figures S1B–S1G and Table S3.
Cell Stem Cell
A Functional Stem Cell Niche Unit in MDSand analyzed for the presence of mutations. These data
show that myeloid and erythroid cells are consistently derived
from the MDS cells (Figures S2A–S2E). Interestingly, contribu-
tion to the lymphoid lineage could also be readily detected
in two of the five patients (MDS25 and MDS16). To experimen-
tally identify the stem cell origin of the DPC in lower-risk MDS,
we FACS purified stem and progenitor populations of two pa-
tients on the basis of lineage negativity (CD235a, CD19, CD4,
CD8, and CD20), CD45 positivity, and CD34 and CD38 expres-
sion and tested their ability to propagate the MDS cells in
NSGS mice (Figure 4A). Each of the four FACS-sorted popula-
tions were injected into two or four mice (depending on the
number of primary cells recovered) and analyzed after 14–
16 weeks posttransplantation for human cell chimerism. As
outlined in Figure 4B, engraftment was achieved exclusively
in mice that had received the LinCD34+CD38 stem cell frac-
tion but not any other cell population. Mutational tracking
confirmed the patient origin of the engrafted MDS cells (Figures
4C and 4D).
Analysis of primary bone marrow cells isolated from patient 18
revealed the presence of three mutations (TET2, U2AF1, and
del(RUNX1)) that we could track with our established workflow
in both NSG and NSGS mice (Figures 3A and 4E–4F). A hetero-
zygous TET2mutation was the most frequent genetic alteration,
and 92% of the cells carried this lesion, as evidenced by a muta-
tional allele frequency of 46%, indicating that this is likely to be
the founder clone in this patient. The other lesions, (U2AF1 and
del(RUNX1)) were detected in 80% and 44%of the cells, respec-
tively (U2AF1 mutational allele frequency = 40%; del(RUNX1)
allele frequency = 22%). These data indicate that these two
lesions are co-occurring and present in subclones that may
have evolved from the founder clone in a linear fashion (Figures4E and 4F). Subsequent analysis of hCD45+ cells isolated
from xenografted mice (two NSG and two NSGS) showed that
del(RUNX1)-bearing cells were not detectable in the NSGS
model (NSGS11 and NSGS12). Similarly, the U2AF1-bearing
clone is largely outcompeted in this model by the founder
TET2-only-bearing clone. In contrast NSG mice display engraft-
ment of all three clones detected in the original patient bone
marrow, albeit at different frequencies (Figures 4E and 4F). Alto-
gether, these data show that we observe simultaneous engraft-
ment of independent clones in the mouse when more than one
clone is present in the patient, therefore closely mimicking the
patient situation (NSG9 and NSG10).
MDS Patient-DerivedMSCs Differ from Healthy MSCs at
the Functional Level
The data in Figure 1Bdemonstrate that coinjection ofMDSMSCs
enhances the engraftment of MDS HSCs in NSG mice. The
in vitro expandedMSCs used in this study fulfill the criteria estab-
lished by the International Society of Stem Cell Therapy in terms
of surface phenotype (CD45HLA-DRCD105+CD73+CD90+
CD44+CD146+; Figure S3A) and were devoid of hematopoietic
cells, including macrophages, as demonstrated by the lack of
CD45 and CD14 expression as well as the undetectable expres-
sion of myeloid specific genes such as cathepsin G (CTSG),
proteinase 3 (PRTN3), and matrix metallopeptidase 9 (MMP9)
in our RNA sequencing data (Figure S3B and data not shown).
In addition, MSCs were functional, given that they were able to
form an ectopic bone marrow niche (ossicle) when coinjected
subcutaneously with hydroxyapatite tricalcium phosphate parti-
cles (HA-TCP), a resorbable bone substitute (Bianco et al., 2013)
(Figure S3C). To directly test whether a specific supporting effect
is exerted by MDS patient-derived MSCs, the identical patientCell Stem Cell 14, 824–837, June 5, 2014 ª2014 Elsevier Inc. 829
Figure 4. Disease-Propagating Stem Cells in Lower-Risk MDS Are Restricted to the Lin–CD34+CD38– Cell Subset and Show Variegated
Clonality
(A) Gating scheme of FACS-sorted populations used for xenotransplantation into NSGS mice. Four fractions were sorted on the basis of CD34 and CD38
expression pregated on live cells (7AAD), lineage negativity (CD19, CD4, CD8, CD20, and CD235a), and positivity for CD45.
(B) Number of injected cells and engraftment results 14–16 weeks posttransplantation.
(C and D) Mutation tracking and quantification by pyrosequencing in all sorted subfractions of the primary patient as well as subpopulations of the human cells
isolated from the engrafted NSGS mice.
(E and F) Detection of variegated clonality by molecular analysis of primary bone marrow cells isolated from patient MDS18 (Pry BM) and hCD45+ cells from the
corresponding xenografted mice. The numbers below the red bars represent the number of del(RUNX1)+ cells scored by interphase FISH over the total number of
cells analyzed. For the primary bone marrow sample, del(RUNX1) was evaluated by SNP array. Data show that the primary MDS patient sample is composed of
three different clones containing successively accumulated mutations in the following order: TET2, U2AF1, and a genomic deletion of RUNX1.
See also Tables S1, S2, and S3.
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matched healthy MSCs obtained from patients undergoing hip
replacement surgery. Our data show that MDS MSCs provided
CD34+ MDS cells with significantly enhanced engraftment ca-
pacity in all five patients tested (p = 0.03; Figures 5A and 5B)830 Cell Stem Cell 14, 824–837, June 5, 2014 ª2014 Elsevier Inc.MDS Patient-Derived MSCs Exhibit Specific Key
Molecular Features, which Can Be Directly Induced by
MDS Cells
To determine whether MDS-derived MSCs are altered, we
compared their transcriptomes with age-matched healthy
Figure 5. Comparison of MDS Engraftment with MDS MSCs as Compared to Age-Matched Healthy MSCs
(A) Exemplary FACS plots depicting differential MDS engraftment of MDS28 patient sample in NSGmice cotransplanted with either MDSMSCs or healthy MSCs
derived from an age-matched donor (left) and inference of the frequency of engrafted MDS cells as determined by multiplication of the fraction of hCD45+ cells
carrying the MDS-specific molecular lesion (here, ASXL1) by the percentage of hCD45+ cells in the bone marrow of engrafted mice (graphs on the right).
(B) Summary of paired analysis performed as described in (A) with five different primary patients (MDS14, MDS28, MDS38, MDS52, and MDS53). Data show a
significant increase in the mean frequency of MDS cells engrafting when using MDS-derived MSCs (one-sided Wilcoxon test; p = 0.03).
See also Table S1.
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This analysis revealed 1,008 differentially expressed genes
(q value < 0.1; 584 upregulated and 424 downregulated in
MDS MSCs; Figure 6A). Gene set enrichment analysis (GSEA)
(Subramanian et al., 2005) revealed that MDS MSCs exhibit a
significant depletion of gene sets associated with adipogenesis
with a concomitant enrichment in gene sets reflective of a
mesenchymal and osteoprogenitors cell fate (Figures S4A and
S4B). In addition, MDS MSCs exhibit signs of ongoing stromal
stimulation and response to an inflammatory environment (Fig-
ure 6B). This is paralleled by the increased expression of genes
associated with fibrosis (LOXL2, SPARC, and ADAMTS4), a
clinical feature often observed in MDS (Figure 6C). Most impor-
tantly, our analysis also identified gene sets including cellular
adhesion, extracellular matrix remodeling, and cytokine-cyto-
kine receptor interaction to be significantly enriched in MDS
MSCs (Figure 6D). These data support the view that patient
MSCs might establish a specific pattern of MSC-hematopoietic
MDS cell interaction within the diseased bone marrow. To vali-
date some of these candidates, real-time RT-PCR, western blot-
ting, and ELISA analysis were performed (Figures 6C, 6E, 6F, and
S4C). Although statistical significance was achieved in the entire
cohort for several factors (VEGF-A, LIF, and ANGPTL4 and
SPARC, IGFBP2, ADAMTS4, and LOXL2), others showed robust
differential expression in only few patients’ samples (CCL26 and
ANG1), reflecting an expected interpatient heterogeneity (data
not shown). CDH2 (N-Cadherin), an important adhesion mole-
cule involved in the control of HSC niche interactions and
MSC-mediated protection of CML progenitors from tyrosine ki-
nase inhibitors (Zhang et al., 2013), is also found to be highly up-
regulated in MDS MSCs (Figure 6E). In addition, despite being
cultured in normoxic conditions, MDS MSCs maintain a strong
hypoxia signature, suggesting that this program is maintainedby cell-intrinsic changes at the genetic or epigenetic level (Fig-
ure S4D). Altogether, these data show that MDS MSCs have
an intrinsically altered pattern of gene expression, including a
number of processes involved in intercellular crosstalk, that
may all contribute to their capacity to support MDS hematopoi-
etic cells in the secondary host.
Finally, in order to test the possibility that hematopoietic MDS
cells may directly induce changes in their surrounding stromal
cells, we developed an in vitro coculture system in order to
evaluate the effect of these cells on a healthy age-matched
stroma. Healthy old MSCs were isolated from several primary
donors and cocultured with either an MDS cell line, MDSL (Mat-
suoka et al., 2010), or primary whole bone marrow isolated from
lower-risk MDS patients (Figures 7A–7C). We FACS purified the
stromal cells 24 hr postincubation and evaluated the expression
of LIF as a read out. The data show strong LIF induction by the
exposure of healthyMSC to theMDSL (Figure 7B) or different pa-
tient-derived primary MDS bone marrow cells (Figure 7C).
Importantly, exposure of the same MSCs to healthy age-
matched bone marrow only marginally affected LIF expression
(Figure 7C). These data indicate that diseased bonemarrow cells
are likely to play an active role in the ‘‘reprogramming’’ of their
bonemarrow niche during disease development and/or progres-
sion by possibly converting it into a self-supportive one.
Notably, in our xenotransplant model, the injected MSCs
(both MDS and healthy) remained present exclusively in the in-
jected bones for up to 4 weeks posttransplantation (Figures
S5A–S5C). However, we could demonstrate engraftment of
MDS-derived cells in both injected and noninjected femurs (Fig-
ure S5D). Combined with the observation that MDS hematopoi-
etic cells can reprogram a healthy niche, these data support a
model in which MDS cells further expand and migrate after the
initial engraftment of the injected bone and then install diseaseCell Stem Cell 14, 824–837, June 5, 2014 ª2014 Elsevier Inc. 831
(legend on next page)
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Figure 7. Exposure of Healthy MSCs to
MDS Bone Marrow Leads to Altered Gene
Expression
(A and B) Experimental scheme and analysis of LIF
expression levels by qRT-PCR in five independent
primary healthy old MSC cultures that were
exposed to an MDS cell line (MDS-L). Data are
depicted as fold change in comparison to theMSC
only control culture.
(C) Analysis of LIF expression levels by qRT-PCR
in four independent primary healthy old MSC
cultures (HY MSC, black bars) that were cocul-
tured with primary bone marrow cells derived from
lower-risk MDS patients (MDS BM, orange bars).
Healthy MSC culture number 1 (MSC1) was
cocultured with samples MDS101 and MDS102
in two independent experiments. MSC2 was co-
cultured with samples MDS101, MDS102, and
MDS111 in three independent experiments. MSC3
was cocultured with samples in five independent experiments (MDS101, MDS102, MDS111, MDS25, andMDS54). MSC4was cocultured with samplesMDS101
and MDS102 in two independent experiments. Statistical analysis reveals that LIF induction is significantly different in settings with versus without MDS cells
(paired Student’s t test, ****p < 0.0001). HealthyMSC2 andMSC3were also exposed to healthy old (65 years old) bonemarrow as a control. Data are presented as
mean fold change in comparison to the corresponding MSC culture only ± SEM. All MSC cultures were depleted of any hematopoietic cells by gating out CD45+
and CD235a+ cells by flow cytometry before being further processed for qRT-PCR analysis (data not shown). n.d., not determined.
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A Functional Stem Cell Niche Unit in MDSto the noninjected bones because of their potential to influence
the mouse bone marrow stromal environment. Future studies
will be necessary to explore the exact mechanism of this
phenomenon.
DISCUSSION
Critically, our study identifies an intricate interplay in humanMDS
between mutant hematopoietic cells and their MSCs. Our data
show that patient-derived hematopoietic cells instruct healthy
MSCs to acquire MDS MSC-like features. In turn, MDS MSCs
produce a number of cytokines and other factors to further
promote the development and expansion of diseased hemato-
poietic MDS stem cells and their progeny. The functional
relevance of this diseased ‘‘hematopoietic niche unit’’ for the
development and progression of MDS in patients is demon-
strated by its capacity to propagate MDS after orthotopic intra-
femoral transplantation into NSG or NSGS mice. In contrast, the
sole transplantation of CD34+ MDS hematopoietic cells by our
group and others only gave rise to inefficient and often transient
engraftment (Martin et al., 2010; Nilsson et al., 2000; Thanopou-
lou et al., 2004). The use of NSGS mice, which produce human
IL3, GM-CSF, and SCF (Wunderlich et al., 2010) as recipients,
not only further enhanced the level of engraftment of humanFigure 6. Molecular Features of MDS MSCs in Comparison to Age-Ma
(A) Heat map of 1,008 differentially regulated genes betweenMDSMSCs (n = 5; pa
age-matched MSCs (n = 3; median age = 74; mean age = 74.4 ± 12) as determin
(B) GSEA of RNA sequencing data showing enrichment for stromal stimulation g
(C) Validation of differential gene expression by quantitative RT-PCR of candidat
healthy MSCs (n = 10; Mann-Whitney test; **p < 0.01; ***p < 0.001; ****p < 0.000
(D) GSEA showing enrichment for adhesion molecules (left), extracellular mat
MDS MSCs.
(E) Western Blot showing differential protein expression of CDH2 (N-Cadherin) a
(F) Confirmation of differential levels of VEGFA and LIF by ELISA in culture supe
(Mann-Whitney test, **p < 0.01, *p < 0.05).
See also Figure S4.MDS but also retained dysplastic morphologic features typical
of MDS pathology. Nevertheless, preliminary data indicate that
patient MSCs remain essential for the efficient engraftment of
lower-risk MDS cells even in the context of NSGS recipients,
further highlighting their essential role in MDS pathogenesis
(data not shown).
Importantly, beyond MDS, other myeloid neoplasms, such as
CML and a subset of AMLs, have proven to be very challenging
to propagate in xenografts. In addition, some studies reported
that AML and MDS MSCs carry karyotype abnormalities that
might hint toward functional significance for disease pathogen-
esis (Blau et al., 2007; Flores-Figueroa et al., 2005). Therefore,
it is tempting to speculate that, similar to lower-risk MDS, CML
and at least the fraction of ‘‘nonengrafter’’ AMLs might fail to
engraft NSGmice because of a lack of a supportive environment.
Niche contribution to these human myeloid neoplasms remains
underappreciated, and our data point to an important area for
future investigations. Consequently, this suggests that higher-
risk MDS or AMLs that are transplantable by injection of
CD34+ cells alone have most likely acquired molecular lesions
allowing them to become independent of the supporting stromal
signals. Alternatively, they exhibit increased potential to rapidly
reprogram the mouse stroma in order to allow disease
propagation.tched Healthy MSCs
tients 14, 16, 17, 18, and 20; median age = 71; mean age = 68.6 ± 4) and healthy
ed by RNA sequencing.
ene sets (left) and inflammatory response (right) in MDS MSCs.
e genes in a larger and independent cohort of MDS (n = 36) and age-matched
1).
rix and receptor genes (middle), and cytokine receptor interaction (right) in
nd IGFBP2 in MDS MSCs as compared to healthy MSCs.
rnatants of MDS derived MSCs in comparison to age-matched healthy MSCs
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A Functional Stem Cell Niche Unit in MDSTo date, there are no surface markers that allow us to distin-
guish MDS stem cells from normal HSCs. Thus, when establish-
ing xenograft models, it is essential to prove that the engrafted
cells are indeed disease-derived as opposed to reflecting the
engraftment of residual healthy HSCs present in the patients’
bonemarrow. Themutational tracking effort in this study demon-
strates that our niche-mediated xenograft model supports the
engraftment of bona fide MDS clones. In total, our approach
revealed significant engraftment in 70% (14 of 20) of the patient
samples transplanted with MDS MSCs. The engraftment
behavior did not correlate with any clinical feature or comorbid-
ities. Importantly, among the 14 patient samples that showed
significant engraftment activity with MDS MSCs, 72% (10 of
14) showed engraftment of an MDS clone, as characterized by
molecular lesion and/or a strong myeloid-biased output,
whereas the remaining 28% (4 of 14) showed coengraftment of
a healthy and an MDS-derived stem cell. Furthermore, the pres-
ence of stem cell (CD34+CD38) and progenitor phenotypes
(CD34+CD38+) in all xenografts 16–28 weeks posttransplanta-
tion, combined with the detection of typical MDS molecular
lesions in both lymphoid and myeloid lineages in xenografts, is
consistent with the engraftment of a patient derived ‘‘diseased’’
stem cell capable of long-term multilineage hematopoiesis. This
finding argues in favor of a multipotent stem cell origin of the
disease, supporting the hypotheses of others (Lawrence et al.,
1987; Tehranchi et al., 2010; Thanopoulou et al., 2004; White
et al., 1994). The demonstration that only LinCD34+CD38
MDS cells are able to transplant the disease further supports
this conclusion and is in line with other myeloid disorders, such
as CML and AML, which are believed to be initiated bymutations
in normal HSCs (Corces-Zimmerman et al., 2014; Jan et al.,
2012; Shlush et al., 2014; Sloma et al., 2010). This is corrobo-
rated by the results showing serial engraftment capacity, even
if the MDS chimerism was relatively low in this setting. However,
similar low levels of engraftment in a serial transplant setting
have also been reported for aged normal HSCs (Dykstra et al.,
2011), reflecting the likely reduced self-renewal capacity of
aged stem cells in mouse and human.
The presence of human preleukemic HSCs, which can survive
chemotherapy and provide a potential source for relapse, has
recently been demonstrated by sequencing human cells in AML
xenografts (Shlush et al., 2014; Corces-Zimmerman et al.,
2014). In addition, whole-exome sequencing revealed that MDS
bone marrow consists of distinct subclones, which are in contin-
uous evolution during disease progression (Walter et al., 2012).
The combination of our xenotransplantation workflow with quan-
titative mutational analyses now allows the investigation of such
clonal composition and hierarchy in MDS in vivo. For example,
our data imply that lower-riskMDS is driven by foundermutations
such as TET2 that initially occur in normal HSCs but then form the
basis for further clonal evolution. Importantly, identification of
mutations present at the stem cell level in the founder clone, as
well as their specific targeting, is of relevance for thedevelopment
of new treatment strategies and disease monitoring.
The identification of patient-derived MSCs as a critical
functional component of lower-risk humanMDSmaywell be rele-
vant for other less aggressive hematological malignancies.
Although it is difficult to exclude the formal possibility that a large
excess of human cells might abrogate ‘‘nonspecific’’ causes of834 Cell Stem Cell 14, 824–837, June 5, 2014 ª2014 Elsevier Inc.decreased engraftment, our data show that, in comparison to
age-matched healthy MSCs, MDS MSCs significantly enhance
MDS engraftment. This strongly argues in favor of the existence
of a specific mechanism by which MDS MSCs support MDS
CD34+ engraftment in vivo. Our data are in line with recent
evidence frommouse genetic studies suggesting that alterations
in niche cells alone are sufficient to drive the development of
myeloid malignancies in mice (Kode et al., 2014; Raaijmakers
et al., 2010;Walkley et al., 2007). All of the factors differentially ex-
pressed between MDS and healthy MSCs, such as LIF (da Silva
et al., 2005; Escary et al., 1993), VEGFA (Rehn et al., 2011),
IGFBP2 (Garcia-Manero, 2012;Huynhetal., 2011), andANGPTL4
(Drake et al., 2011; Zheng et al., 2012), are known to promote sur-
vival and proliferation of both mouse and human HSPCs. Our
finding that some of these factors can be induced by exposure
of healthy MSCs to diseased primary MDS bone marrow cells,
but not a healthy age-matched counterpart, is consistent with
recent reports suggesting that leukemic cells can alter their niche
counterpart in geneticmousemodels of CMLandAML (Schepers
et al., 2013; M. Hanoun, 2013, Am. Soc. Hematol., abstract).
These data support the view that a specific pattern of MSC-
hematopoietic cell interaction exists within the diseased bone
marrow and most likely contributes to the progressive bone
marrow clonality and fibrosis frequently observed in MDS
patients. Thanks to this approach, it is now possible to dissect
the cellular and molecular components of this MDS niche unit
in vivo, whichmay lead to the design of targeted strategies aimed
at disrupting essential MDS MSC niche interactions. Moreover,
the possibility to efficiently establish MDS xenografts from
lower-risk MDS patients generates a platform for personalized
oncology. Patients are still alive at the time the models are estab-
lished, allowing assessment and possibly targeting of MDS
pathology at the level of individual patients.
EXPERIMENTAL PROCEDURES
Detailed procedures can be found in the Supplemental Experimental
Procedures.
Patient and Healthy Donor Bone Marrow Samples
MDS samples were collected from diagnostic bone marrow aspirations of
MDS patients treated in the Department of Hematology and Oncology of the
University Hospital Mannheim, Germany, after written informed consent.
Bone marrow samples of healthy age-matched donors were obtained
from residual femur specimen accrued from hip replacement surgery after
written informed consent. The use of human samples was approved by the
Institutional Review Board of the Medical Faculty Mannheim, University of
Heidelberg, Germany, in accordance with the Declaration of Helsinki. Patient
characteristics are summarized in Table S1.
Molecular Analyses
High-Density SNP Array Analyses
High-density SNP array analysis was carried out as previously reported
(Nowak et al., 2012).
Screening for Commonly Mutated Genes in MDS
NGS with a screening panel for commonly mutated genes in MDS was
performed as previously described (Grossmann et al., 2013; Kohlmann
et al., 2011). In addition, exome sequencing was performed on an Illumina
HiSeq2000 platform.
Pyrosequencing
For all mutations detected in MDS samples (single-nucleotide variations and
InDels up to 4 bp), custom primer sets for validation and molecular tracking
Cell Stem Cell
A Functional Stem Cell Niche Unit in MDSwere designed. Pyrosequencing and data analysis were performed on a
Pyromark ID system (QIAGEN).
Fluorescence In Situ Hybridization
Interphase FISH was performed with the following probes: XL 5q33, D-5057-
100-OG, XL AML1, and D-5027-100-OG (Metasystems), and quantitative
analyses were carried out in the Munich Leukemia Laboratory.
RNA Sequencing Analysis and GSEA
RNA transcriptome sequencing was performed on a HiSeq2000 platform
(Illumina). Aligned reads were converted into count tables with the htseq-count
program version 0.5.4 with the gene annotation file used for read mapping.
Differentially expressed genes were called with the DESeq2 package in
R/Bioconductor according to the procedure outlined in the vignette. Correc-
tion for multiple testing was performed with the Benjamini-Hochberg proce-
dure. All genes were ranked according to their log fold change and submitted
to the Pre-Ranked GSEA tool and compared with 3,786 gene sets from the C2
collection of MSigDB.
Quantitative RT-PCR
RNA samples were transcribed with the SuperScript VILO cDNA synthesis kit
according to the manufacturer’s instructions with additional oligo-dT primers
(Invitrogen). Quantitative RT-PCR was performed with the ABI Power SYBR
Green Master Mix (Life Technologies). PCR reactions were performed on a
Viia7 (Life Technologies) with the primers listed in Supplemental Experimental
Procedures.
Flow Cytometry Analysis and Cell Sorting
FACS analysis was performed on a BD LSR Fortessa, and sorting was per-
formed on FACSAria II and FACSAria III systems (BD Biosciences). Antibodies
used are described in the Supplemental Experimental Procedures. The FACS-
sorted populations used in the experiments described in Figures 3D and 3E
were reanalyzed and showed over 98% purity (data not shown).
Mouse Experiments
NSG and NSGS mice were purchased from the Jackson Laboratory. Females
6–8 weeks of age were sublethally irradiated (200 cGy) before the cells were
injected in the femoral bone marrow cavity. All xenotransplants were per-
formed with 105 CD34+ cells along with 5 3 105 MSCs unless otherwise indi-
cated. Sample preparation is described in the Supplemental Experimental
Procedures. Where indicated, fine needle aspirates from the noninjected
femur were performed in order to estimate engraftment. Primary mice were
analyzed 16–28 weeks posttransplanation unless indicated otherwise. For
secondary transplants, FACS-sorted cells were mixed with MDS MSCs and
injected according to the same procedure used for primary mice. Animals
were housed under specific pathogen-free conditions at the central animal
facility of the German Cancer Research Centre. All animal experiments were
approved by the Animal Care Committee under Tierversuchsantrag numbers
G74/12 and G210/12.
ACCESSION NUMBERS
The RNA sequencing data has been uploaded to the European Genotype
Archive database for European Bioinformatics Institute and can be accessed
under accession number EGAS00001000716.
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five figures and three tables and can be found with this article online at
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